Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 45,506

Document Document Title
WO/2013/158121
The present invention relates to crystalline solvate forms of N-[2,4-bis(1,1- dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3 -carboxamide (Compound 1) and methods for their preparation. The present invention further relates...  
WO/2013/155716
Disclosed is a capsule to improve sleep, comprising Ganoderma lucidum extract, Spina date seed extract and Folium Ginkgo extract. The capsule has multiple nutritious and health-preserving components, is easy to prepare and can improve sl...  
WO/2013/157511
The invention provides a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, R1 is an optionally substituted C6-10 aryl group or an optionally substituted 5- to 12-membered monocyclic or p...  
WO/2013/156329
The invention relates to the prophylactic and therapeutic applications of certain estrogenic components such as estetrol in neurological disorders such as neonatal hypoxic-ischemic encephalopathy (HIE).  
WO/2013/158628
The present invention is directed to a composition for the treatment or prevention of cerebral malaria that comprises an angiotensin receptor type-2 agonist and an antimalaria drug. The present invention is further directed to methods fo...  
WO/2013/156850
Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.  
WO/2013/156505
The present invention relates to 1,4-benzothiazepine derivatives and their use to treat conditions, disorders and diseases associated with ryanodine receptors (RyRs) that regulate calcium channel functioning in cells. The invention also ...  
WO/2013/156035
The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5-HT1B, 5-HT1D and 5-HT1F receptors, such as a triptan, e.g. zolmitriptan, in a matrix constituent with exten...  
WO/2013/156614
The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the ...  
WO/2013/158739
A therapeutic composition for treating brain injury comprising a polyarginine peptide of from 5 to 9 arginines, and further comprising 1 or more terminal cysteines. The composition is administered in therapeutically effective dosages pro...  
WO/2013/156231
Provided herein are compounds for use in the treatment of neuropathic pain and the neuropathic pain syndromes, in particular the use of imidazotriazinones. Pharmaceutical compositions, single unit dosage forms, and kit suitable for use f...  
WO/2013/156232
Provided herein are compounds for use in the treatment of neuropathic pain and the neuropathic pain syndromes, in particular the use of benzofuranylsulfonates. Pharmaceutical compositions, single unit dosage forms, and kit suitable for u...  
WO/2013/155586
The present technology describes a process for preparing inclusion compounds in continuous flow enclosing drugs and cyclodextrins, which is coupled to spray-dryer equipment. This process allows better control of the injection and of the ...  
WO/2013/156955
The present invention refers to diamine oxidase for use in the treatment or prevention of attention deficit hyperactivity disorder (ADHD).  
WO/2013/153535
The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as m PGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (m PGES-1) enzyme and are ...  
WO/2013/154712
This invention is directed to asymmetric syntheses of certain spiro-oxindole derivatives, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.  
WO/2013/154410
The present invention relates to the field of medicine, in particular to a novel use of phenobarbital (PhB) in the treatment of autonomic dysregulation disorders. Long-term treatment reduces the sympathetic hyperactivity encountered duri...  
WO/2013/154409
The present invention relates to medicine. It describes a novel use of Venlafaxine in the treatment of autonomic dysregulations with sympathetic deficit, more specifically symptomatic dysautonomic bradycardia subsequent either to substan...  
WO/2013/155054
Compositions, methods of making compositions and methods of treating cough are described herein. In some embodiments, the compositions are lozenges comprising memantine and an alkalinizing agent.  
WO/2013/152704
Disclosed in the present invention is a class of 5-amino-1,4-dihydro-1,8-naphthyridine derivatives and the pharmaceutical composition and use thereof. The class of 5-amino-1,4-dihydro-1,8-naphthyridine derivatives of the present inventio...  
WO/2013/153155
The object of the present invention is the use of the noncoding RNA particles (microRNA) and antagomirs for microRNA in medicine, in particular for prevention and treatment of autoimmune diseases, in particularly for multiple sclerosis.  
WO/2013/152717
Disclosed are a fused pyrimidine compound as represented by formula (I), pharmaceutically acceptable salt, hydrate, and solvate thereof, an optical isomer or a prodrug thereof, as well as a preparation method, an intermediate, a composit...  
WO/2013/154128
The present invention pertains to: the use as the target of treatment for dyslipidemia, hyperlipidemia, arteriosclerosis, or Alzheimer's disease of a gene coding for the human CTNNB1, human NFE2L2, human TXN, human CUL1, human RAE1, huma...  
WO/2013/154109
Provided is a therapeutic drug for diseases associated with central nervous system (CNS) and/or peripheral nervous system (PNS) cholinergicity, diseases associated with smooth muscle contraction, endocrine diseases, diseases associated w...  
WO/2013/153451
Pharmaceutical formulations containing opioid components that each has a release profile. The components may provide immediate or controlled release of the opioid. The invention is also directed to methods of controlling release of one o...  
WO/2013/154744
The invention is directed to a conjugate which comprises an isolated adenovirus hexon protein coupled to nicotine or a nicotine analog, as well as a method of inducing an immune response against nicotine in a human by using the conjugate.  
WO/2013/151729
Provided herein are methods of reducing and/or inhibiting A deposition or A plaque formation in the brain, and/or inhibiting or slowing the progression of disorders mediated by A deposition or A plaque formation using therapeutically eff...  
WO/2013/150529
The invention provides indole and indoline derivatives and slats thereof, compositions comprising them and uses thereof for the treatment of diseases and disorders.  
WO/2013/150406
This invention relates to the compound (4aαH-3,5α,8aß-trimethyl-4a,9-tetrahydro- naphtho[2,3-b]-furan-8-one) known as siphonochilone, and related compounds, useful in mammals in supporting, promoting and maintaining health, and in the...  
WO/2013/151281
The present invention provides a composition containing Mori Cortex Radicis extract as an active ingredient for preventing or treating depression. The present invention exhibits an anti-stress effect by suppressing the nuclear translocat...  
WO/2013/149384
Brain atrophy prevention agent comprising a phospholipid as an active ingredient is disclosed. The phospholipid contains a highly unsaturated fatty acid as a constituent fatty acid.  
WO/2013/150117
The invention relates to a compound of formula (I), where: n is an integer equal to 0 or 1; R1 is, when n=0, an alkyl chain having 3 to 6 carbon atoms, an alkenyl chain, alkylene, a linear hydroxyalkyl chain having 2 to 6 carbon atoms, t...  
WO/2013/149996
The present invention belongs to the field of EPl receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EPl receptor. The invention also refers to the process for ...  
WO/2013/149976
The present invention relates to new indole-pyrimidine derivatives of Formula (I), a process for obtaining them, a pharmaceutical composition comprising said compounds and their use in the treatment of several disease including cognitive...  
WO/2013/152105
This invention relates to novel pharmaceutical compositions comprising a therapeutica11y effective combination of a dopaminergic stabilizer known as Pridopidine, and an inhibitor of the vesicular monoamine transporter type 2 (VMAT) known...  
WO/2013/149997
The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for ...  
WO/2013/149580
Provided herein are timosaponin compounds of Frmula I, II, IIΙ, I', II' and IIΙ', pharmaceutical compositions comprising the coumpounds, and processes of preparation thereof. Also provided are uses of said timosaponin compounds for pre...  
WO/2013/149800
The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also rela...  
WO/2013/150529
The invention provides indole and indoline derivatives and slats thereof, compositions comprising them and uses thereof for the treatment of diseases and disorders.  
WO/2013/152291
A method of reducing a symptom of radiation exposure in a subject is provided. The method includes a step of introducing mammalian cells into the subject, the mammalian cells having been treated ex vivo to insert therein a polynucleotide...  
WO/2013/149996
The present invention belongs to the field of EPl receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EPl receptor. The invention also refers to the process for ...  
WO/2013/151832
The present invention provides compounds of Formula I: wherein A is selected from the group consisting of; (a), (b), (c) and (d), R1 is H or F; R2 is H, —CH2OH, C1-C3 alkyl, (e), or (f);; R3 is H, F, or CN; R4 is H, F; or CN; and R5 is...  
WO/2013/150303
This invention relates to stem cell microparticles, their use and production, in particular neural stem cell microparticles and their use in therapy. The stem cell microparticle is typically an exosome or microvesicle and may be derived ...  
WO/2013/149470
Disclosed is a new application of a bisbenzylisoquinoline derivative shown in formula (I) in the specification or pharmaceutically acceptable salt thereof. The application is an application of the bisbenzylisoquinoline derivative shown i...  
WO/2013/150173
Compounds of formula (I), wherein X and R1-R6, are as defined in the claims, exhibit alpha2 agonistic activity and thus useful as alpha2 agonists, especially as alpha2A agonists. Methods of use of said compounds are also provided.  
WO/2013/152350
The subject invention pertains to myricanol derivatives, therapeutic compositions, and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau.  
WO/2013/149506
Provided in the present invention is a chimeric peptide based on opioid peptide Biphalin and NPFF. Also provided in the present invention are the synthesis method for the chimeric peptide and the use thereof in preparing analgesic drugs....  
WO/2013/150542
Disclosed is a transdermal patch for treatment of degenerative neurological disorders like dementia or Alzheimer type dementia. More particularly, the transdermal patch for treatment of neurodegenerative disorder comprises anadhesive mon...  
WO/2013/150295
The present invention relates to a food supplement to support brain function, including cognitive functions such as memory. The food supplement comprises one or more active ingredients selected from the group consisting of uridine, cytid...  
WO/2013/150150
This disclosure relates to methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline- 7-sulfonamide in a disease modifying therapy of Alzheimer's disease, other tauopathies and relate...  

Matches 551 - 600 out of 45,506